Traditional chimeric antigen receptor (CAR) T-cell manufacturing requires extended ex vivo cell culture that reduces stem cell memory T cells and antitumor activity. In this study, Dickinson and colleagues assessed the preclinical development and the initial clinical evaluation of YTB323, an autologous CD19-directed CAR T-cell therapy that is manufactured using a next-generation process in less than 2 days. Use of YTB323 in preclinical mouse models demonstrated enhanced in vivo expansion and antitumor activity at lower doses than traditionally manufactured CAR T cells, while, in adults with relapsed/refractory diffuse large B-cell lymphoma, YTB323 showed promising safety and clinical activity at a 25-fold lower dose than tisagenlecleucel.
See article, p. 1982.
The clinical benefit generated by FGFR inhibition in patients with FGFR-driven urothelial cancer is mitigated by the onset of resistance. Facchinetti and colleagues performed sequencing analyses on postprogression tissue biopsies and circulating tumor DNA from 21 patients with FGFR...
